Skip to main content

Table 2 Patients treated with caspofungin

From: Caspofungin for treatment of invasive aspergillosis in Germany: results of a pre-planned subanalysis of an international registry

Type of use Monotherapy
(N = 36)
Combination therapy
(N = 6)
Total
(N = 42)
Caspofungin first-line therapy* 10 (28%) 1 (17%) 11 (26%)
Caspofungin second-line therapy** 26 (72%) 5 (83%) 31 (74%)
   Thereof reason for switching to caspofungin
   Clinically refractory to first-line therapy 21 (58%) 5 (83%) 26 (62%)
   Toxicity with first-line therapy 2 (6%) 0 2 (5%)
   Other** 3 (8%) 0 3 (7%)
  1. *The reason for using caspofungin as the first line therapy was "probable aspergillosis" in 10 patients and "proven aspergillosis" in 1 patient.
  2. **In 25 patients, this consisted of azoles (9 posaconazole, 7 voriconazole, 6 fluconazole (of these, 5 for prophylactic use and 1 for unknown reasons), 3 itraconazole), in 5 patients polyenes (2 amphotericin colloidal dispersion, 3 liposomal amphotericin B), and in 1 patient other antimycotics. Prior antimycotic therapy had been given for a mean duration of 13.2 days.
  3. **Breakthrough infection during azole prophylaxis